If you were going to partner up you might want to have some legal experts look things over and help negotiate for you!!!!
Two Boston investment firms were among a group sanctioned by the Securities and Exchange Commission for illegally short-selling stocks and then participating in offerings of those stocks by public companies.
The SEC on Tuesday named 18 hedge funds and private equity firms and one individual trader in a crackdown on a certain kind of short-selling violation — betting a stock’s value will fall in advance of share offerings by companies, which can depress the stock’s sale price. The investors then purchased shares in the subsequent offerings.
In total, the funds and firms agreed to repayments and penalties worth a combined $9 million.
A Boston firm that invests in health care and life sciences companies, RA Capital Management, agreed to pay $3.6 million to settle the charges. The SEC said that on 17 occasions, from June 2009 through July 2013, RA Capital bought shares from an underwriter or broker participating in a public stock offering, after having shorted the same stock within the prior five days.
RA Capital, with $1.4 billion in assets, reaped $2.6 million in profits by short-selling pharmaceutical and biotech secondary stock offerings by companies including ImmunoGen Inc. of Waltham.
The SEC said such activity often results in illicit profits for the investment firms or individuals, while reducing the offering proceeds for the company by artificially depressing its market price.
A Boston hedge fund firm, Midwood Capital Management, also agreed to settle the SEC’s charges, for nearly $143,000. On two occasions from 2010 through February 2012, the firm that manages $145 million shorted shares during the restricted period before buying the stock in a secondary offering.
Neither firm was available for comment. The SEC said the firms took remedial action and cooperated with the regulator.
The SEC last year announced that it was going to step up enforcement of a regulation designed to prevent stock price manipulation.
Huston we have a problem...... 20 million short shares have to even up and be accounted for on the new exchange. Oppsy somehow there are more short shares then are physically available. Hummmmm the blood is about to flow Standby for toasted shorty.
On Monday Sept 15th
We will also launch additional cancer clinical studies to further characterize and expand the potential of our DNA immune therapy products and immune activators with their potent abilities to generate and activate the highest levels of antigen-specific killer T cells. These include trials for INO-5150 for prostate cancer with our pharmaceutical partner in Q3 and INO-1400, our immunotherapy encoded for hTERT in breast, lung and pancreatic cancer patients later this year. Our goal is to have the best and most extensive pipeline of active cancer immunotherapies with the potential to seek out and destroy cancer cells," said Dr. Kim.
Somebody knows a good thing when they see it.
The CEO of Inovio Pharmaceuticals Inc (INO), Jong Joseph Kim recently bought 250K shares for $2,265K on August 12. The average price per share was $9.06. on the other side, Dr. Kim articulated on the company’s website that their next generation vaccines have the possible to further enhance health and prolong life around the world. Inovio Pharmaceuticals Inc (NYSEMKT:INO) reported the gain at 1.23% and closed at $10.71 with the total traded volume of 1.36M shares. Its market capitalization was $646.87M. The stock owned by the Financial Institutions was 19%. The company’s shares have lost -17.49% in last 30 days and 33.88% in previous three months.
In a Phase 1 trial of VGX-3100, Inovio demonstrated that this HPV immunotherapy produced high levels of durable T cell immune responses, notably CD8+ T cells, in 78% of all patients. These CD8+ T cells showed the functional ability to kill target cells displaying the antigens E6 and E7. In preclinical animal models, this DNA-based immunotherapy demonstrated 100% protection against HPV E6 and E7-expressing tumors and prevented or delayed the growth of such tumors. The proprietary IL-12 immune activator, called INO-9012, was previously shown to enhance antigen-specific CD4+ and CD8+ T cell immune responses to Inovio's Pennvax HIV DNA vaccine in a clinical trial. Inclusion of this DNA-based immune activator in INO-3112 is intended to further strengthen the generation of HPV-specific CD8+ T cells to treat HPV-caused cancer.
This cervical cancer study is being conducted at the University of Chicago Medical Center and at the Comprehensive Cancer Center at Silver Cross, Ill, where Dr. Yasmin Hasan, director of Gynecological Radiation Oncology and Brachytherapy, is the principal investigator.
Dr. J. Joseph Kim, Inovio's president and CEO, said, "This study extends our pioneering HPV immune-based treatment into cervical cancer, the No. 2 cancer killer of women in the world. Our goal is to fully address the post-HPV infection immune therapeutics markets, targeting not only HPV-related cervical pre-cancer but also cervical cancer as well as head and neck and anogenital cancers."
"Cancer immunotherapy is focused on generating cancer fighting T cells and freeing them to attack targeted cancer cells. Inovio has demonstrated that its therapies mobilize more antigen-specific T cells than any other product on the market or in development. We look forward to reporting unblinded cervical dysplasia Phase 2 study data on efficacy and T cell responses by the end of July. Our aim is to have the best and most extensive pipeline of active cancer immunotherapies with the potential to seek out and destroy cancer cells," said Kim.
That we don't Hummmm $400k is putting your money where your mouth is.
Transaction Date Insider Name Title Buy/Sell Number of Shares Average Share Price Total Transaction SEC Link Share
8/20/2014 Morton Collins Director Buy 40,600 $9.74 $395,444.00 View Tweet This Trade Share This Trade on StockTwits
8/12/2014 Jong Joseph Kim CEO Buy 250,000 $9.06 $2,265,000.00 View Tweet This Trade Share This Trade on StockTwits
4/15/2014 Jong Joseph Kim CEO Buy 25,000 $2.25 $56,250.00 View
Morton Collins, a director of Inovio Pharmaceuticals, recently acquired 40,600 shares of the company. The buys took place at prices ranging from $9.71 to $9.75 per share, on August 20, 2014. Collins now owns 245,691 shares of the company. Collins operates out of Plymouth Meeting, PA. Some additional info was provided as follows:
•September 8, 2014 Rodman & Renshaw 16th Annual Global Investment Conference
•September 11, 2014 Aegis Capital Healthcare & Technology Conference
• September 17, 2014 CANCER ANTIBODIES VACCINES/ADJUVANTS & DELIVERY
•September 26, 2014 4th International Conference on Vaccines & Vaccination
•October 6, 2014 Cancer Vaccines and Gene Therapy (CVGT) Meeting Monday,
•October 7, 2014 Bernstein's Oligo/Gene Therapeutics Event
•October 13, 2014 World Vaccine Congress 2014 Monday,
•October 28, 20143rd International Conference and Exhibition on Cell & Gene Therapy
•November 18, 2014 Stifel Healthcare Conference,
•December 2, 2014Piper Jaffray Healthcare Conference,
*****Cancer Vaccines and Gene Therapy (CVGT) Meeting (PA) - Phase II Efficacy Study Results*****
Day 1, MONDAY, 06 October 2014
8:30 - 9:00
*Late Breaking Presentation* Unknown company
Matthew Morrow, Immunology Lead, Inovio Pharmaceuticals
VGX-3100 HPV Specific Immunotherapy for Cervical Intraepithelial Neoplasia: Phase II Efficacy Study Results
Day 2, TUESDAY, 07 October 2014
8:30 - 9:00
*Late Breaking Presentation* Unknown company
Stephanie Ramos, Sr. Scientist, Inovio Pharmaceuticals
Enhancing DNA Vaccination by Intradermal and Intramuscular Electroporation
The 2014 CVGT meeting will be held at The Desmond in Malvern Pennsylvania is a one-of-a-kind hotel, conveniently located in one of Pennsylvania’s most scenic and historic settings.
Jumping on at the west coast. I suggest we stop for unique food along the way. BBQ, Southwest, Fresh and local etc. Would enjoy a stop in Cancun on the way over or during the return flight for the fishing and sea food..
Looks like INO has a ways to go up!!
Hi VJ looks like we both are on the road a bit. I travel around the west for work. I enjoy the challenge but some hotels are not always comfortable. Sometimes i am out of cell and internet range for a few days too. Enjoy your home and own bed.